BGI Group (formerly Beijing Genomics Institute) is a leading global genomics and life‑science company headquartered in Yantian District, Shenzhen, founded in 1999 to participate in the Human Genome Project. Today it integrates research, technology and industry across non‑profit and commercial arms, with operations in more than 100 countries and regions and a mission of “Omics for All.”

Main products and businesses

• Next‑generation sequencing platforms and instruments
  Through its subsidiary MGI Tech (SSE: 688114), BGI develops and manufactures DNBSEQ next‑generation sequencing platforms, reagents and lab automation systems used in precision medicine, precision agriculture and precision healthcare worldwide.

• Genetic testing and precision‑medicine services
  BGI Genomics (SZSE: 300676) provides clinical genetic testing and high‑throughput sequencing services in reproductive health (such as the NIFTY non‑invasive prenatal test), oncology, infectious diseases and chronic disease management, serving medical institutions and research organizations in 100+ countries.

• Integrated laboratory and public‑health solutions
  BGI offers Huo‑Yan (“Fire Eye”) laboratory solutions, RT‑PCR tests and large‑scale multi‑omics platforms that support epidemic response, population‑health projects and national gene‑bank initiatives.

• Research, multi‑omics and synthetic‑biology platforms
  BGI‑Research, the group’s research arm, operates the China National GeneBank and advances basic and applied research in genomics, transcriptomics, proteomics, metabolomics and synthetic biology, supporting collaborations with academia and industry.

Key advantages

• End‑to‑end genomics ecosystem
  BGI spans the full value chain from sequencing instruments and reagents to clinical testing, bioinformatics, big‑data platforms and public‑health solutions, enabling tightly integrated “instrument + service + data” offerings.

• Global scale and scientific heritage
  With around 10,000 employees and a footprint covering China, Asia‑Pacific, the Americas, Europe, the Middle East and Africa, BGI leverages two decades of participation in landmark genomics projects to deliver large‑scale, high‑throughput omics services.

• Broad application coverage in health and beyond
  Its technologies support precision medicine, reproductive health, oncology, infectious‑disease control, agriculture, environmental protection and other fields, helping governments, hospitals and enterprises apply omics data to real‑world challenges.

If you want, I can now compress this into a concise 3–4 sentence English profile in your “company + main products + advantages” format for your comparison table.